Healthcare
Prelude Therapeutics Incorporated(PRLD)
Live Price
Offline$4.32
-0.69% today
1Y Change
+430.95%
Window
Jun 23, 2025 โ Jun 15, 2026
- Market Cap
- $260.00M
- Revenue Growth
- +73.4%
- EPS Growth
- +23.2%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 23, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Prelude Therapeutics Incorporated (PRLD) is a Healthcare stock with a market cap of $260.00M and listed on NASDAQ. The stock last traded around $4.32 and up 431.0% across the available one-year price window (Jun 23, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of +73.4%, EPS growth of +23.2%, a dividend yield of 0.0%. What stands out right now is revenue +73.4%, EPS +23.2%, free cash flow +45.6% with operating margin -861.3% and ROIC -114.8%. Valuation already assumes a fairly strong business story at price/sales 21.6. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines PRLD price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+73.4% vs +7.6% peer median
Operating Margin
Below sector median
-861.3% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 5, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +73.4% and EPS at +23.2%, with operating margin around -861.3%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +2.7% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 5, 2026 | โ | +3.6% | -0.6% | -21.6% |
2026 Mar 10, 2026 | +39.4% | +5.8% | -4.7% | +17.2% |
2025 Nov 12, 2025 | +25.7% | +2.7% | +13.6% | +10.9% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PRLD
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
PRLD Max Drawdown
-70.10%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PRLD and SPY.
Company Overview
Prelude Therapeutics Incorporated
NASDAQ Global Select
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.
- Leadership
- Krishna Vaddi
- IPO Date
- Sep 25, 2020
- Employees
- 131
- Street Address
- 200 Powder Mill Road
- Mailing
- Wilmington, DE, 19803
- Region
- Wilmington, DE, US
- Reporting Currency
- USD
- Investor Line
- 302 467 1280
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 21.6
- Price/Book
- 4.3
Growth
- Revenue
- +73.4%
- EPS
- +23.2%
- Free Cash Flow
- +45.6%
Profitability
- Gross Margin
- 93.1%
- Operating Margin
- -861.3%
- Net Margin
- -819.6%
- ROE
- -130.0%
- ROIC
- -114.8%
Balance Sheet
- Debt/Equity
- 0.26
- Current Ratio
- 1.99
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.